Wave Life Sciences Ltd. (WVE) Revenue History
Annual and quarterly revenue from 2013 to present
WVE Revenue Over Time (2013–2025)
WVE Revenue Growth History
7 of 10 years with positive growth- FY2013 revenue growth
- N/A
- FY2014 revenue growth
- N/A
- FY2015 revenue growth
- N/A
- FY2016 revenue growth
- +877.0%
- FY2017 revenue growth
- +149.4%
- FY2018 revenue growth
- +289.1%
- FY2019 revenue growth
- +10.9%
- FY2020 revenue growth
- +25.6%
- FY2021 revenue growth
- +104.0%
- FY2022 revenue growth
- -91.1%
- FY2023 revenue growth
- +3005.1%
- FY2024 revenue growth
- -4.4%
- FY2025 revenue growth
- -60.5%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $38.2M | +316.9% |
| Q4 2025 | $17.2M | -79.4% |
| Q3 2025 | $7.6M | +199.1% |
| Q2 2025 | $8.7M | -55.8% |
| Q1 2025 | $9.2M | -26.8% |
| Q4 2024 | $83.7M | +188.2% |
| Q3 2024 | $-7,676,000 | -115.6% |
| Q2 2024 | $19.7M | -10.9% |
Multi-year avg. share of annual revenue by fiscal quarter
WVE Revenue Analysis (2013–2025)
Current Revenue & Growth
As of June 12, 2026, Wave Life Sciences Ltd. (WVE) generated trailing twelve-month (TTM) revenue of $71.8 million, reflecting explosive growth of +316.9% year-over-year. The most recent quarter (Q1 2026) recorded $38.2 million in revenue, up 121.8% sequentially.
Historical Growth Trajectory
WVE's 5-year compound annual growth rate (CAGR) stands at +16.3%, indicating consistent double-digit revenue growth. The 3-year CAGR of +127.1% exceeds the 5-year average, indicating an acceleration in the most recent period. Wave Life Sciences Ltd.'s highest annual revenue of $113.3 million was recorded in 2023.
Peer Comparison
Compared to Healthcare sector peers — including SRPT (-2.2% YoY), IONS (+47.5% YoY), and ARWR (+14.1% YoY) — WVE has outperformed the peer group in revenue growth. Compare WVE vs SRPT →
WVE Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
 WVECurrent | $72M | +316.9% | +16.3% | -504.1% | |
 SRPT | $2.2B | -2.2% | +32.4% | -29.9% | |
 IONS | $944M | +47.5% | +5.3% | -40.5% | |
 ARWR | $829M | +14.1% | +56.6% | 11.9% | |
 NTLA | $68M | +45.0% | +3.1% | -651.7% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% |
WVE Historical Revenue Data (2013–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $42.7M | -60.5% | $33.9M | 79.3% | $-215,383,000 | -504.1% |
| 2024 | $108.3M | -4.4% | $108.3M | 100.0% | $-110,403,000 | -101.9% |
| 2023 | $113.3M | +3005.1% | $113.3M | 100.0% | $-67,996,000 | -60.0% |
| 2022 | $3.6M | -91.1% | $3.6M | 100.0% | $-162,720,000 | -4459.3% |
| 2021 | $41.0M | +104.0% | $41.0M | 100.0% | $-127,016,000 | -310.1% |
| 2020 | $20.1M | +25.6% | $-110,867,000 | -552.2% | $-153,377,000 | -763.9% |
| 2019 | $16.0M | +10.9% | $-159,448,000 | -997.6% | $-208,317,000 | -1303.4% |
| 2018 | $14.4M | +289.1% | $-120,014,000 | -832.6% | $-159,523,000 | -1106.7% |
| 2017 | $3.7M | +149.4% | $-75,605,000 | -2041.2% | $-102,580,000 | -2769.4% |
| 2016 | $1.5M | +877.0% | $1.1M | 73.5% | $-55,327,000 | -3725.7% |
| 2015 | $152K | - | $-8,905,000 | -5858.6% | $-19,298,000 | -12696.1% |
| 2014 | $0 | - | $-2,395,000 | - | $-5,394,000 | - |
| 2013 | $0 | - | $-4,608,000 | - | $-3,574,000 | - |
What if you invested $1,000 in WVE back in 2013?
Total return with dividends reinvested · 13+ years of data
Calculate ReturnsHow much would $100/month in WVE be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs WVE Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationWVE vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowWVE — Frequently Asked Questions
Quick answers to the most common questions about buying WVE stock.
Is WVE's revenue growth accelerating or slowing?
WVE revenue growth is accelerating. TTM revenue reached $72M, up +316.9% year-over-year — ahead of the 5-year CAGR of +16.3%. This indicates the business is expanding faster than its historical baseline.
What is WVE's revenue history from 2013 to 2026?
Wave Life Sciences Ltd. (WVE) revenue history spans 2013 to 2026. TTM revenue as of 2026 is $72M, growing at +316.9% YoY. The 5-year CAGR is +16.3%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is WVE's long-term revenue growth rate (CAGR)?
Wave Life Sciences Ltd.'s 5-year revenue CAGR of +16.3% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +316.9% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for WVE.
Why does WVE's quarterly revenue fluctuate?
WVE quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Wave Life Sciences Ltd.'s revenue data from 2013 to 2026 shows full historical quarterly detail on this page.
How is WVE's revenue distributed by segment?
WVE reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does WVE's revenue compare to industry peers?
Wave Life Sciences Ltd. (WVE) with TTM revenue of $72M and +316.9% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.